African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study

被引：0
|
作者：
Cole, Craig [1 ]
Opalikhin, Anne [2 ]
McCartney, Matthew [3 ]
Heideman, Caroline [4 ]
Pentapati, Swetha [4 ]
Wang, Ling [5 ]
机构：
[1] Michigan State Univ, Karmanos Canc Inst, E Lansing, MI 48824 USA
[2] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA
[3] Michigan State Univ, Coll Osteopath Med, McLaren Greater Lansing, E Lansing, MI 48824 USA
[4] Michigan State Univ, Karmanos Canc Inst, McLaren Greater Lansing, E Lansing, MI 48824 USA
[5] Michigan State Univ, Coll Human Med, Dept Med, Div Occupat & Environm Med, E Lansing, MI 48824 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-241
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [31] Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
    Tomer, Mark
    Lucio, Gordan
    David, Ray
    Stephen, Ijioma
    George, Dranitsaris
    Amanda, Warner
    Trevor, Heritage
    Matthew, Fink
    David, Wenk
    Shachar, Peles
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S24 - S24
  • [32] Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
    White, Darrell J.
    LeBlanc, Richard
    Baljevic, Muhamed
    Bahlis, Nizar J.
    Lentzsch, Suzanne
    Venner, Christopher P.
    Gasparetto, Cristina
    Chen, Christine I.
    Lipe, Brea
    Tuchman, Sascha A.
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    Callander, Natalie S.
    Bensinger, William I.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Zhou, Tianjun
    Kazuharu, Kai
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Schiller, Gary J.
    BLOOD, 2020, 136
  • [33] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [34] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bassali, J.
    Gould, I
    Mladsi, D. D.
    Kaye, J. A.
    Shah, J.
    Mehta, J.
    VALUE IN HEALTH, 2020, 23 : S33 - S33
  • [35] A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Gould, Ian
    Bassali, Jan
    Mehta, Jyotsna
    Shah, Jatin
    Mladsi, Dee Dee
    BLOOD, 2019, 134
  • [36] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Janet A. Parsons
    Nicole R. Greenspan
    Natalie A. Baker
    Chris McKillop
    Lisa K. Hicks
    Olivia Chan
    BMC Cancer, 19
  • [37] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [38] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Parsons, Janet
    Greenspan, Nicole
    Baker, Natalie
    McKillop, Chris
    Hicks, Lisa
    Chan, Olivia
    BMC CANCER, 2019, 19 (1)
  • [39] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [40] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    HAEMATOLOGICA, 2013, 98 : 614 - 614
12345